BNC Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

BNC Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,356	Closed	-$6.21M	–	105
2024 Q3	$6.21M	Buy	+13,356	New	+$6.42M	2.29%	10
2024 Q2	–	Sell	-5,405	Closed	-$2.26M	–	108
2024 Q1	$2.26M	Buy	+5,405	New	+$2.28M	0.97%	33
2023 Q4	–	Sell	-8,070	Closed	-$2.81M	–	109
2023 Q3	$2.81M	Buy	8,070 +209	+3%	+$73.1K	1.51%	24
2023 Q2	$2.77M	Buy	+7,861	New	+$2.65M	1.47%	22
2020 Q4	–	Sell	-7	Closed	-$2K	–	454
2020 Q3	$2K	Buy	+7	New	+$1.93K	﹤0.01%	462

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BNC Wealth Management's VRTX Position: Q4 2024 in Review

BNC Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 13,356 shares — an estimated $6.21M sold.

BNC Wealth Management first reported a position in VRTX in Q3 2020 and held it in 5 quarters. The position peaked at $6.21M in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

BNC Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
BNC Wealth Management sold 13,356 Vertex Pharmaceuticals shares in Q4 2024, an estimated $6.21M.
BNC Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 5 quarters.
BNC Wealth Management's Vertex Pharmaceuticals position peaked at $6.21M in Q3 2024.
1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on BNC Wealth Management's 13F filing for Q4 2024, filed 15 Jan 2025.